Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

by · The Cerbat Gem

Sera Prognostics (NASDAQ:SERA – Get Free Report) posted its earnings results on Thursday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03, FiscalAI reports. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.10 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA traded down $0.17 on Thursday, hitting $2.95. The stock had a trading volume of 14,532 shares, compared to its average volume of 180,458. The company has a market capitalization of $111.13 million, a price-to-earnings ratio of -3.47 and a beta of 0.97. Sera Prognostics has a twelve month low of $1.37 and a twelve month high of $9.13. The firm’s 50 day moving average price is $3.17 and its 200-day moving average price is $2.68.

Insider Buying and Selling

In related news, CEO Zhenya Lindgardt sold 21,158 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total value of $66,647.70. Following the completion of the transaction, the chief executive officer owned 811,136 shares in the company, valued at $2,555,078.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 52,627 shares of company stock worth $159,853. 13.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sera Prognostics

Several large investors have recently modified their holdings of SERA. Qube Research & Technologies Ltd acquired a new position in shares of Sera Prognostics in the second quarter valued at about $92,000. Corient Private Wealth LLC lifted its position in shares of Sera Prognostics by 73.9% during the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock worth $277,000 after buying an additional 42,500 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of Sera Prognostics by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after purchasing an additional 100,366 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Sera Prognostics by 4.6% during the third quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock worth $3,725,000 after buying an additional 54,008 shares during the last quarter. 54.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

SERA has been the topic of several recent research reports. Wall Street Zen raised Sera Prognostics from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on SERA

Sera Prognostics Company Profile

(Get Free Report)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

Read More